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One important goal of the pharmaceutical industry is to evaluate new therapies in a
time-sensitive and cost-effective manner without undermining the integrity and validity of
clinical trials. Adaptive seamless phase II/III designs (ASD) have gained popularity for
accelerating the drug development process and reducing cost. Covariate adaptive
randomization (CAR) is the most popular design in randomized controlled trials to ensure
valid treatment comparisons by balancing the prognostic characteristics of patients among
treatment groups. Although adaptive seamless clinical trials with CAR have been
implemented in practice1, the theoretical understanding of such designs is limited. In addition,
current approaches to control the Type 1 error rate in seamless trials are based on theories for
complete randomization, which may be invalid under CAR and lead to a Type 1 error rate
that deviates from the nominal level. Recently, Ma and Zhu (2019, unpublished) established
the theoretical foundation for the adaptive seamless phase II/III trial with CAR and proposed
a hypothesis testing approach to control the Type 1 error rate in such trials. In the current

research, numerical studies were conducted to investigate the feasibility and advantages of
the proposed approach in the seamless design with stratified permutated block (SPB)
randomization. The simulation results revealed that the newly developed method well
controlled the Type 1 error rate around the nominal level, improved the statistical power
compared to the standard two sample t-test and increased the number of replications that the
best treatment is selected for Stage II of the seamless trial under the SPB design compared to
the complete randomization, which could promote its application in practice.
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BACKGROUND
Literature Review
1. Randomized Controlled Trials
Randomized controlled trial (RCT) is a study that divides subjects into distinct groups
by random process to compare the effect of treatments or other interventions. It is the gold
standard in clinical research due to its potential to minimize various biases and inherent
strength to unveil casuality2. Randomization, in conjugation with the controlled and blinding
provides a powerful tool to achieve accurate and valid estimates of the treatment effects for
various medical interventions.
1.1 Randomization methods
1.1.1 Simple randomization
One key feature of RCT is randomization, which helps to ensure that the treatment
and control groups are well balanced in both measured and unmeasured factors. Many
procedures have been implemented in randomization of RCTs. Simple randomization, which
is equivalent to repeated fair coin-tossing, is the most basic method for random
assignments3,4. It prevents any conscious or unconscious selection bias by assigning subjects
to treatment groups completely at random. In a large clinical trial (n > 200), simple
randomization allows adequate balance in both sample size and prognostic factors (ie.
covariates) among treatment groups5. However, accidental bias may occur due to chance
imbalances in group sizes and pre-specified covariates when the trial size is small (n < 100) 5,6.
These imbalances can impair the precision and validity of comparisons among treatments and
are often blamed for failures in clinical trials7. Therefore, randomization techniques that help
1

ensure balanced group sizes and baseline characteristics have been largely adopted in
practice in contrast to simple randomization6.
1.1.2 Permuted block randomization
Permuted block randomization (PBR) is the most commonly used method to balance
the number of subjects allocated to each treatment group8. Blocks are small and balanced
with predetermined treatment assignments, ensuring equal number of subjects in each
treatment group through the whole trial process. Block size is often a multiple of the group
number. All permutations for the block size (ie. all possible combinations of treatment
assignments within the block) are listed once the block size is determined, from which the
treatment allocation for a subject is decided by random selection of the permutations.
Although PBR can help ensure balanced number of subjects in each treatment group to
maximize statistical power, the baseline covariates among groups may not be comparable,
resulting in confounding bias and impaired power of the study4,5.
1.1.3 Stratified permuted block randomization
To achieve covariate balance in clinical trials6,8, multiple coactive-adaptive
randomization (CAR) approaches have been proposed, among which stratified permuted
block randomization is the most common one in both academia and industry sponsored
clinical trials6,9,10. In a trial using stratified PBR, subjects are divided into different strata
based on measurable prognostic factors that are considered strongly associated with the
primary outcome, such as trial centers and disease stages. The total number of strata is the
product of the number of levels across the covariates. Permuted block randomization is then
performed within each stratum to assign a subject to one of the treatment groups 11. Stratified
2

PBR helps achieve proper balance in both group sizes and pre-specified covariates, leading to
maximal statistical power and minimal confounding bias. However, only a small number of
prognostic factors can be balanced using this procedure. When there are too many influential
covariates or covariates with many levels in the trial, a large number of strata will be
generated. Some strata may have few or even no subjects if the trial is small, resulting in
imbalances in overall treatment allocations and jeopardizing the validity of the study.
Therneau et al. showed that the balance in covariates begins to fail if the total number of
strata is greater than approximately half of the sample size12. One early study indicated that
the number of strata should be less than N/B to maintain the benefits of stratified PBR, where
N is the total sample size and B is the block size13. Kerman suggested a more stringent
number by multiplying B with a safe factor 4 in the denominator (ie. N/4B) 14. In practice, a
mean of 2.52 (SD = 0.90) stratification variables were used in clinical trials with stratified
PBR6.
1.2 Traditional clinical trial design
Conventional drug and medical intervention development consists of a sequence of
independent RCTs organized in different phases. To develop a novel drug for certain disease
in a classical way, pre-clinical investigations are firstly carried out to study drug’s safety,
pharmacodynamics and pharmacokinetic on animals and to evaluate drug production and
purity. If the study results are promising, the drug is further investigated in human subjects in
four sequential phases after approval by US Food and Drug Administration (FDA) for each
phase. In phase I trials, drug’s safety, maximum tolerated dose and human
pharmacodynamics and pharmacokinetic are tested in 20 to 100 healthy volunteers or people
3

with the disease/condition. Phase II trials, also referred to as exploratory or learning phase
trials, provide preliminary evidence of drug efficacy besides further investigating the safety
and pharmacological issues in a larger diseased population (up to several hundred). In these
trials, multiple doses of a new drug may be compared to a control (ie. conventional treatment
or placebo) to decide whether to stop or continue with the development. Data collected in this
phase can also help to refine research questions, develop research methods and design
research protocols for phase III trials. Known as pivotal studies, phase III trials demonstrate
or confirm treatment efficacy and identify incidence of side effects in a population ranging
from 300 to 3000 subjects. The trials can last up to 4 years and sometimes more than one
phase III trials are required to establish drug efficacy and safety by FDA. Because of the
large scope and long duration of the trials, long-term and rare side effects are more likely to
be detected in the studies. Statistical analyses for phase III trials are typically conducted by
ignoring data collected in previous phases, and the outcome measures are usually different
from phase II trials. Phase IV trials are conducted once the drug is approved by FDA during
the post-market safety monitoring. More rare adverse reactions can be identified and health
economic evaluations could be implemented in this phase15,16.
1.3 Adaptive seamless phase II/III design
To accelerate the process of drug development and reduce its cost, adaptive seamless
phase II/III designs (ASD) have been developed, whereby the two phases are combined into
a single, uninterrupted trial with two or more stages. Typically, the stages are separated by
one or more interim analyses, at which several experimental treatments or drug doses are
evaluated. At these interim looks, experimental treatments are either dropped for futility or
4

continued to be investigated in the later stage(s) due to high treatment efficacy. Adaptions
such as sample size reassessment are allowed after the interim analyses 17,18.
1.3.1 Principle of ASD
A simple scenario of ASD is comparing multiple experimental treatments with one
control in a two-stage design with one interim analysis. Based on the data from the learning
stage I (analogous to the traditional phase II), the study is either stopped due to futility or
continued to the confirmatory stage II (analogous to the traditional phase III) along with the
empirically best experimental treatment and the control. The final analysis of the selected
treatment includes information from both stages and the overall type one error of the
statistical analysis is controlled at a pre-specified level independent of the selection rule at
the interim. Bauer and Kӧhne proposed a test procedure for this scenario in 199419. Generally,
a one-sided null hypothesis corresponding to comparing different effects between two
treatments is tested. The test procedure for Stage I, the stopping rule for the interim analysis
and the combination test for the final analysis are pre-determined. Hypothesis testing for
Stage I results in a p-value p1 , to which the interim decision is made accordingly. If the study
is continued, the second stage can be re-designed, e.g, sample size is re-assessed, and a pvalue p 2 is obtained from hypothesis testing for Stage II. The two p-values are combined in
the end using the pre-specified combination test to decide whether the null hypothesis is
rejected or not17.
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1.3.2 Combination tests
In the above adaptive test procedure proposed by Bauer and Kӧhne, fisher’s
combination test, i.e. the inverse  2 method was recommended19. Fisher’s criterion results in
rejection of the null hypothesis at the end of the two-stage trial if
− log( p1 p 2 )   42,1− / 2 ,

where  42,1− is (1 −  )th quantile of a  2 distribution with 4 degrees of freedom.
Another common approach for combination test is the weighted inverse normal
method20. For an adaptive seamless phase II/III trial with two stages, given two one-sided pvalues, p1 and p 2 from each stage, the method rejects the null hypothesis in the final
analysis if

w1 −1 (1 − p1 ) + w2  −1 (1 − p2 )   −1 (1 −  ) ,
where w1 and w2 are pre-specified weights satisfying 0  wi  1, i = 1,2 and w12 + w22 = 1 . 
denotes the standard normal CDF. A widely adopted option is wi = ni n , i = 1,2 , where n i
are the pre-planned sample sizes for the two stages and n = n1 + n2 18.
2. Multiplicity in Clinical Trials
Multiplicity is defined as simultaneous assessments of multiple aspects of the efficacy
profile in a clinical trial21. It may inflate type I error rate and lead to increased risk of false
positive conclusions in trials which evaluate multiple end points, compare across several
treatment arms, analyze multiple sub-populations and measure the same outcome repeatedly
in time22,23. For example, in an exploratory dose-comparison study with two dose candidates,
6

or in a confirmatory trial with two primary end points, two true null hypotheses (i.e. no
treatment effect) are tested simultaneously at significance level  , which refers to the
probability of a type I error. The probability of rejecting at least one true null hypothesis,
known as overall type I error rate or familywise error rate (FWER), can be calculated as

1 − (1 −  ) 2 . When  = 0.05 , FWER is 0.0975, indicating that there is 9.75% of chance to
declare at least one significant treatment effect when indeed none is significant by the trial
sponsors, whereas others believe that the type I error rate is maintained at the level of 5%.
Besides inflating type I error rate, multiplicity also has important implications for sample size
determination24. Therefore, multiplicity adjustment is mandated by regulatory agencies to
ensure accurate efficacy or safety claims 25,26.
2.1 Multiplicity adjustments in clinical trials
Numerous multiplicity adjustment methods, i.e. multiple testing procedures (MTPs)
have been developed to solve multiplicity problems in clinical research. Identifying the most
appropriate MTP for a particular clinical trial is essential to maximize the statistical power.
In practice, clinical trialists customize solutions for addressing multiplicity by utilizing all
available clinical and statistical information. When definitive clinical information is available,
hypotheses for each individual objective, e.g. each end point in a phase III trial, can be
ordered in a clinical meaningful way prior to data analysis. Data-driven hypothesis ordering
will be used if a meaningful priori ordering cannot be pre-specified. Based on distributional
information, MTPs can be classified into nonparametric tests, semiparametric tests and
parametric tests, in which parametric tests are the most efficient but rely on specific
7

statistical assumptions. Methodology and applications of commonly used MTPs in clinical
trials are thoroughly reviewed by Bretz et al27. and Dmitrienko et al21,22. Two methods,
Simes test and Dunnett test are introduced here because they will be used in the proposed
numerical study.
2.1.1 Simes test
Simes test is a single-step MTP that assumes non-negative correlations between pvalues of individual hypotheses and is more powerful than a global test based on Bonferroni
test. Assume a multiplicity problem arising in a trial which compares k experimental
treatments with a control. K null hypotheses denoted by H 1 ,..., H k correspond to evaluations
of treatment effects parameterized as 1 ,..., k , i.e., H i :  i = 0, i = 1,..., k . The Simes method
tests the global null hypothesis

H = H i : 1 = ... =  k = 0, i = 1,..., k .
Let p(i ) , i = 1,..., k be ordered p-values for individual hypotheses. With p(1)  ...  p( k ) , the
test rejects H if p(i )  i k for at least one i. Simes’ adjusted p-value is min i kp(i ) i .
2.1.2 Dunnett test
Dunnett test is a single-step parametric test assuming that the correlations between the
test statistics are known. It provides less conservative multiplicity adjustment and is more
powerful than the nonparametric test such as Bonferroni test. For the above multi-arm trial
example, we want to test the k null hypotheses

H i :  i = 0, i = 1,..., k .
The test statistics are defined as
8

ti =

yi − y0
s 1 ni + 1 n 0

, i = 1,..., k ,

where y i and y 0 are sample mean, and n i and n0 are sample size for treatment k and
control, respectively. s is the pooled sample standard deviation and s 2 = i =0 (ni − 1) S i2  ,
k

where S i2 is the sample variance for treatment k and  = i =0 ni − k − 1 . Under the null
k

hypotheses, (t1 ,..., t k ) follows k-variate t-distribution with  degrees of freedom and
correlations

 i, j =

ni
ni + n 0

nj
n j + n0

, i, j = 1,..., k .

For the k null hypotheses, dunnett test rejects H i if t i  ck ,1− , where c k ,1− is determined by

Pr[(t1 ,..., t k )  (ck ,1− ,..., ck ,1− )] = Pr(max i t i  ck ,1− ) = 1 −  .
2.2. Closure principle
Closure principle proposed by Marcus et al.28 is a general construction method which
allows one to draw conclusions for individual null hypothesis in multiple testing following a
closed test procedure (CTP). It strongly controls FWER and serves as the foundation for all
commonly used MTPs in clinical trials21. For a multi-arm trial where k experimental
treatments are compared with a control, k null hypotheses H i :  i = 0, i = 1,..., k are to be
tested, where  i is the treatment effect. These initial hypotheses are called elementary
hypotheses in the CTP. All possible intersection hypotheses, i.e., H I =  H i , I  {1,..., k}
iI

are constructed, and a local level-α test is performed for each of the intersection hypotheses.
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An elementary hypothesis H i is rejected at FWER α if all H I with i  I are rejected, each
at local level α, i.e., the maximum p-value from this set needs to be less than or equal to α.
The adjusted p-value for H i is qi = max p I , i = 1,..., k , where p I denotes the p-value for a
I :iI

given intersection hypothesis H I , I  {1,..., k} . Multiple MTPs can be used for different
intersection hypotheses17.
2.3 Multiple testing in ASD
The general idea for multiple testing in adaptive design is to construct all intersection
hypotheses for each stage and to test each of the hypotheses with a suitable combination
test17,29. Consider a simple two-stage seamless phase II/III design whereby two experimental
treatments 1 and 2 are compared with a control in Stage I. Assume treatment 1 is selected in
the interim analysis to go forward to Stage II, and we are interested in testing the null
hypothesis H 1 : 1 = 0 in the final analysis, where  1 is the treatment effect for treatment 1.
Following the CTP, intersection hypothesis H 12 is constructed and hypotheses H 1 , H 2 and

H 12 are to be tested for both stages. Let pi , j denote the one-sided p-value for hypothesis
H j , j  {1,2,12} at stage i = 1, 2. Denote combination function C derived from the inverse  2
method or the weighted inverse normal method. Since treatment 2 is dropped at the interim
and no data is available for it in Stage II, H 12 for the second stage is equal to H 1 and the test
is performed on data for treatment 1 in this stage. According to closure principle, H 1 is
rejected at FWER α in the final analysis if H 1 and H 12 for both stages are simultaneously
rejected at the significance level α, i.e., if C ( p1,12 , p 2,1 )  c and C ( p1,1 , p 2,1 )  c .
10

Public Health Significance
Randomized controlled trials have been the gold standard for discovering efficient
treatments and understanding counter-balancing risks. Many breakthroughs in disease
prevention and treatment in the past century are attributable to RCTs, such as the landmark
Salk Polio Vaccine Trial30 and trials for tuberculosis control31,32. Ford et al. reported that
approximately half of the decrease in the age-adjusted death rate for coronary heart disease
from 1980 to 2000 can be attributed to medical therapies validated in clinical trials33. More
than 200,000 clinical trials worldwide have been registered in the US National Institute of
Health (NIH) today34, leading medical innovations to improve health and well-being of
human race.
One main barrier to conducting clinical trials in the US is high financial costs35. The
estimated cost to develop and win marketing approval for a new drug had increased from
US$802 million in 2003 to US$2.6 billion in a decade36. Lengthy timelines contribute
directly to the costs of clinical trials. The average length of time from the start of clinical
testing to marketing is 7.5 years37, and typically 10 to 15 years are spent from discovery to
registration with FDA for a drug therapy38. Long development process also reduces the time
a drug has under patent protection, allowing early entry of generic competitors and reducing
revenue for the patent holder. These obstacles may discourage pharmaceutical companies
from investing in drug development and consequently limit patients’ access to novel
treatments.
The motivation behind adaptive seamless phase II/III designs is to save time for drug
development. By combining the conventional phase II and III trials into one study, ASD
11

reduce the lead time between the two phases. It also increases data collection and
interpretation efficiency while maintaining the same sample size by combing information in
the final analysis. Alternatively, smaller sample sizes are required in the ASD to draw
conclusions with the same strength as in the traditional designs. Furthermore, long-term
safety data can be obtained earlier because patients in the learning stage I are continued to be
monitored in the confirmatory stage II in the ASD.
In contrast to high financial costs, the clinical trial success rate is low. A recent study
revealed that only 14% of drugs in clinical trials win FDA approval eventually, and the
success rates range from 3.4% for cancer treatments to 33% in vaccines for infectious
diseases39. Strict control of type I error rate at a two-sided 5% level is mandated for FDA
approval25. For clinical trials with CAR, conventional tests are usually used without
consideration of the randomization scheme40. Failing to incorporate all stratification
covariates used for randomization into inference procedures results in conservative tests in
terms of small type I error rate and reduced statistical power 41, therefore beneficial treatments
may be denied to patients.
In this proposal, simulation studies are proposed to examine a new hypothesis testing
procedure which is able to well calibrate the type I error rate at the significance level under
CAR in adaptive seamless phase II/III clinical trials. The success of the research will
facilitate the implementation of the procedure in the adaptive seamless trials with CAR to
increase the trial success rate, leading to more efficient and cost effective clinical trials that
benefit the general population related to the corresponding medical innovations.

12

Hypothesis, Research Question, Specific Aims or Objectives
1. Research questions and hypotheses
For seamless trials, type I error rate tends to inflate due to multiplicity and selection42.
Classic MTPs such as Dunnett test can well control the type I error rate in the ASD with
simple randomization, assuming independence of each patient 43. Under CAR, however, the
assumption is no longer true due to the complicated randomization mechanism aiming to
balance covariates over different arms. For example, balancing covariates via stratification
leads to correlation between the treatment groups44. For a scenario where one experimental
treatment is compared to one control, it is reported that the classic tests are too conservative
in terms of small type I errors when stratified PBR is used to allocate patients44. It is unclear
if MTPs such as Simes test and Dunnett test are valid under CAR with multiple treatments in
the setting of seamless designs, and if not, how to perform adjustment to achieve valid tests.
Zhu and Ma have studied the properties of intersection tests under CAR with multiple
treatments, and have provided theoretical results for a hypothesis testing approach where
Simes and Dunnett tests are still valid under CAR in the seamless design (unpublished).
Suppose there are ( K + 1) arms in Stage I of a seamless clinical trial with CAR, in which K
experimental treatments are compared to a control, and the total sample size is N . Let

 k , k = 0,1,..., K be the parameter measuring the main effects of treatment k . Testing the K
null hypotheses H 0,k :  k =  0 , k = 1,..., K and their interactions are of interest. Let

Ti = (Ti 0 , Ti1 ,..., TiK ) T , i = 1,..., N be the treatment assignment of the ith subject, where
treatment 0 represents the control arm. Tik = 1, k = 0,1,..., K , if the ith subject is assigned to
13

treatment k , and Tik = 0 otherwise. The number of subjects in treatment k is

N k = i =1 Tik , k = 0,1,..., K . Let Yi = (Yi 0 , Yi1 ,..., YiK ) T , i = 1,..., N be a random vector of
N

response variables, where Yik , k = 0,1,..., K is the response of the ith subject assigned to
treatment k . Yk = i =1 Tik Yik N k is an estimator of  k . Let Z i be the covariate information
N

for the ith subject, which is independent and identically distributed. For simplicity, Z i s are
assumed to be either discrete or continuous covariates. To incorporate continuous covariates
in randomization, Z i is discretized with D( Z i ) , a discrete function of Z i taking values in Ɒ.
D ( Z i ) = Z i is set for discrete covariates. The response of the ith subject under treatment k

follows the linear model

Yik =  k + Z i +  ik , k = 0,1,..., K ,
where  represents the covariate effect, and  ik s are independent and identically distributed
random errors from the normal distribution N (0,  2 ) , and are independent of covariates.
Two conditions are introduced for the balancing properties under CAR with multiple
treatments: (A) N k − N 0 = O p (1), k = 1,..., K ; (B)

i=1 (Tik − Ti 0 ) I{D(Z i ) = d} = O p (1), k = 1,..., K
N

for any d  Ɒ.

The following theorems show how to construct test statistics for H 0,k :  k =  0 , k = 1,..., K
that can be used for the Simes test and the Dunnett test.
Theorem 1: Let

14

Xk =

Yk − Y0

 d 1 Nk +1 N0

, k = 1,..., K ,

where  d2 =  2 +  2 E[Var{Z i | D( Z i )}].

(1)

Under conditions (A) and (B), when all H 0,k :  k =  0 , k = 1,..., K are true, we have
d
( X 1 ,..., X K )T ⎯
⎯→
N (0, R) ,

1
1
where R = diag{ I K } + I K I TK .
2
2
Based on the theorem, the test statistic follows a standard normal distribution for
every single test for H 0,k :  k =  0 , k = 1,..., K , and the critical value can be selected
accordingly to one-sided or two-sided tests. In practice, the value of  d can be estimated by
model-based or bootstrap methods.
Theorem 2 (The Simes test): Under conditions (A) and (B), the Type I error rate is
controlled for the Simes test with the test statistic X k , k = 1,..., K under CAR.
Original Dunnett test is based on the multivariate t distribution. In Theorem 1, it is
proved that the vector of test statistics ( X 1 ,..., X k ) T asymptotically follows K dimensional
normal distribution with unit variances and constant correlations equal to 1/2. Without loss of
generality, the alternative hypotheses are assumed to be H1,k :  k   0 , k = 1,..., K . The null
hypotheses are rejected if max k X k  c' , where c' is determined by

Pr[( X 1 ,..., X k )  (c' ,..., c' )] = Pr(max k X k  c' ) = 1 −  . The above test procedure is referred
to as modified Dunnett test.
15

Theorem 3 (The Dunnett test): Under conditions (A) and (B), the type I error rate is
asymptotically  for the modified Dunnett test using test statistic X k , k = 1,..., K under
CAR.
Numerical studies, also known as simulation studies are computer experiments which
create data by pseudo-random sampling from known probability distributions. They are
excellent tools for evaluating novel statistical methods and comparing competing approaches.
To assess the appropriateness and accuracy of the hypothesis testing procedure mentioned
above in a seamless design with CAR, numerical studies are proposed to use in the current
study with following aims.
2. Specific Aims
I. Detect potential problems in type I error control for commonly used hypothesis
testing procedures in seamless phase II/III clinical designs with covariate adaptive
randomization.
II. Implement the newly developed hypothesis testing procedure in seamless designs
with covariate adaptive randomization to better control the type I error rates.
III. Demonstrate the statistical advantage of the new hypothesis testing procedure under
the alternative hypothesis in seamless designs with covariate adaptive randomization.

16

METHODS
Study design
A seamless phase II/III trial design with two stages under stratified permuted block
randomization (SPB) was considered and numerical studies were conducted based on the
following settings. There were ( K + 1) arms under study in Stage I, in which K
experimental treatments were compared to a control. Patients were sequentially assigned to
all the arms with SPB based on M covariates. One experimental treatment k * with the
largest estimated treatment effect was selected at the end of the stage. In stage II, the planned
number of patients was sequentially assigned to the control and the treatment k * with SPB
based on M covariates. The hypothesis H

0,k *

:

k*

=  0 vs.  k *   0 was tested based on

the combined data from both stages. Scenarios with different number of treatments and
stratification covariates, i.e., (1) K = 2, M = 2 ; (2) K = 3, M = 3 ; (3) K = 4, M = 2 were
evaluated. For Scenario 1, both discrete and continuous stratification covariates were studied.
Simulation procedures
In Scenario 1, two experimental treatments (i.e., treatment 1 and treatment 2) were
compared with one control (i.e., treatment 0) in Stage I, and both discrete and continuous
stratification covariates were considered. The following linear model with two covariates Z 1
and Z 2 was used to simulate response Yi ,

Yi =  0 + 1Ti1 +  2Ti 2 + 1 Z i1 +  2 Z i 2 +  i ;
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where Ti1 and Ti 2 were indicator variables indicating the treatment assignment of the ith
subject. Tik = 1, k = 1,2 if the ith subject was assigned to treatment k , and Tik = 0 otherwise.

 1 and  2 were the addictive effects of treatments on outcome, and 1 and  2 were
coefficients corresponding to the stratification covariates. For the discrete case, Z 1 and Z 2
followed Bernoulli distributions with success rates p1 and p 2 , respectively. For the
continuous case, Z 2 was generated from standard normal distribution and discretized into
bernoulli variable D( Z 2 ) with probability p 2 to be used in SPB randomization. More
specifically, D( Z 2 ) = 1 if Z 2  Z ( p2 ) , where Z ( p2 ) was the p 2 quantile of the standard
normal distribution, and D( Z 2 ) = 0 otherwise. Continuous covariate was used in statistical
inference procedures.  0 ,  1 and  2 were assigned value of 1, and  i ~ N (0,  2 ) . 120
patients were assumed to sequentially enter the trial in Stage I, and the block size of 6 was
used for SPB randomization with respect to covariates Z 1 and Z 2 . Complete randomization
(CR) was also implemented. To select the experimental treatment to go forward to Stage II,
Let

Wk =

Yk − Y0
S k2 / N k + S 02 / N 0

, k = 1,2 ,

(2)

where Yk was the mean response for the treatment k , k = 1,2 , Y0 was the mean response for
the control, S k2 and S 02 were the unbiased estimators of the variance for the treatment k and
the control, respectively. The experimental treatment with larger W , denoted as treatment k *
was considered more effective and selected to continue.
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In Stage II, 500 patients were simulated and allocated into the control and the
treatment k * using SPB randomization with respect to the two covariates or complete
randomization. The hypothesis tests for comparing treatment effects in both stages included
the two-sample t-test without adjustment, full linear model with both covariates Z 1 and Z 2 ,
the bootstrap t-test proposed by Shao et al.45, and the newly developed procedure denoted as
t-test with adjustment. For the bootstrap t-test, B bootstrap samples ( Y1*b , Z1*,1b , Z1*,b2 ),…,(

YN*b , Z N*b,1 , Z N*b, 2 ), b = 1, 2,…, B were generated independently by random sampling with
replacement from ( Y1 , Z1,1 , Z1, 2 ) ,…, ( YN , Z N ,1 , Z N , 2 ). SPB randomization with categories
defined by the covariate values of each bootstrap sample ( Z 1*,1b , Z 1*,b2 ) ,…, ( Z N*b,1 , Z N*b, 2 ) was
*b
applied and the bootstrap analogues of treatment allocations T1*kb ,..., TNk
could be obtained,

where Tik*b = 1, k = 0,1,2 if the ith subject was assigned to treatment k , and Tik*b = 0
otherwise. Define the treatment effects between the experimental treatments and the control
as

Y j*b − Y0*b =

1
n *jb

N

 Tij*bYi*b −
i =1

1
n0*b

N

N

N

i =1

i =1

i =1

 Ti*0bYi*b , n0*b =  Ti*0b ,n*jb =  Tij*b , j = 1,2 .

The bootstrap estimator of the variance of Y j − Y0 was the sample variance of Y j*b − Y0*b , b =
1/ 2
1, 2,…,B, denoted by v̂ Bj . The bootstrap t-test had the test statistic TB = (Y j − Y0 ) vˆ Bj . B =

200 was used in the current simulations. For the t-test with adjustment based on Theorem 1,
the value of  d was computed by formula (1), where values of   and  were estimated by
fitting a full linear regression model with both covariates. The closed test procedures using
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Dunnett test and Simes test were applied for hypothesis testing to control the familywise
error rate (FWER). Hypothesis H 0,k* :  k* =  0 vs. H1,k* :  k *   0 for the seamless design
was tested using Fisher’s combination test at the end of the stage. According to the closure
principle, H 0,k* was rejected at FWER  if H 0，12 and H 0,k* were both rejected at  , i.e.,

C ( p1,12 , p 2,k * )  c and C ( p1,k * , p 2,k * )  c . The significance level  was 0.05 for all the
tests. All the results were based on 10, 000 replications.
In Scenario 2, three experimental treatments (i.e., treatment 1, 2 and 3) were
compared with one control (i.e., treatment 0) in Stage I, and three discrete stratification
covariates ( Z 1 , Z 2 and Z 3 ) were considered. The following linear model was used to
simulate response Yi ,

Yi =  0 + 1Ti1 +  2Ti 2 +  3Ti 3 + 1Z i1 +  2 Z i 2 +  3 Z i 3 +  i ;
where Ti1 , Ti 2 and Ti 3 were indicator variables indicating the treatment assignment of the ith
subject. Tik = 1, k = 1,2,3 if the ith subject was assigned to treatment k , and Tik = 0
otherwise.  1 ,  2 and  3 were the addictive effects of treatments on outcome, and  1 ,  2
and  3 were coefficients corresponding to the stratification covariates. Z 1 , Z 2 and Z 3
followed Bernoulli distributions with success rates p1 , p 2 and p3 , respectively.

 i ~ N (0,  2 ) . CR and SPB randomization with respect to all the three covariates were
implemented. In Scenario 3, four experimental treatments (i.e., treatment 1, 2, 3 and 4) were
compared with one control (i.e., treatment 0) in Stage I, and two discrete stratification
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covariates ( Z 1 and Z 2 ) were considered. The following linear model was used to simulate
response Yi ,

Yi =  0 + 1Ti1 +  2Ti 2 +  3Ti 3 +  4Ti 4 + 1Z i1 +  2 Z i 2 +  i ;
where Ti1 , Ti 2 , Ti 3 and Ti 4 were indicator variables indicating the treatment assignment of
the ith subject. Tik = 1, k = 1,2,3,4 if the ith subject was assigned to treatment k , and Tik = 0
otherwise.  1 ,  2 ,  3 and  4 were the addictive effects of treatments on outcome, and  1
and  2 were coefficients corresponding to the stratification covariates. Z 1 and Z 2 followed
Bernoulli distributions with success rates p1 and p 2 , respectively.  i ~ N (0,  2 ) . CR and
SPB randomization with respect to the two covariates were implemented.
In both scenarios, sample sizes for Stage I and II were 200 and 400, respectively. The block
sizes for the SPB design are 8 and 10, respectively. Other settings were the same as in
Scenario 1.
Type I error rates were calculated as the rate of rejection of H 0,k* :  k* =  0 in the
two-stage seamless design among all 10,000 simulation replications assuming  k =  0 in
Stage I and  k * =  0 in Stage II. Powers were computed as the rate of rejection of

H 0,k* :  k* =  0 in the two-stage design among all 10,000 simulation replications assuming

 k   0 in Stage I and  k *   0 in Stage II. Number of replications that the best treatment is
selected for Stage II was the counts that treatment 1 was selected at the end of Stage I among
all 10, 000 simulation replications assuming treatment 1 had the largest treatment effect.
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RESULTS
To study Type 1 error rates, no difference in treatment effects was assumed by
assigning  1 =  2 = 0 . Results from Scenario 1 were reported in Table 1 (discrete case) and
Table 2 (continuous case). Under CR in both cases, Type 1 error rates were close to the
nominal level 5% for both the two sample t-test (t-test) and the full linear model (lm(Z1, Z2)).
Under the SPB randomization with either Dunnett test or Simes test for multiplicity
adjustment, the two-sample t-tests were conservative with Type I error rates far below 5%,
while the t-tests with adjustment (Adjusted-t) successfully controlled Type 1 error rates
around 5%. Type 1 error rates were also well controlled when the full linear model and
bootstrap t-test (BS-t) were used in both discrete and continuous cases. Different values of
( p1 , p 2 ,  ) were investigated and similar results were obtained as shown in the tables.
Table 1: Simulated Type I error under stratified permuted block design (SPB) and
complete randomization (CR) in % in the seamless trial with three treatments and two
discrete covariates.
MTP

(p1, p2, σ)

Simes

(0.5, 0.5, 1.0)
(0.4, 0.6, 1.0)
(0.4, 0.6, 1.5)

Dunnett

(0.5, 0.5, 1.0)
(0.4, 0.6, 1.0)
(0.4, 0.6, 1.5)

Allocation
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR
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t-test
1.73
5.00

lm(Z1, Z2)
5.26
4.73

1.78
4.73
3.00
4.61

4.84
4.80
4.78
4.65

1.98
5.20

5.75
5.30

1.91
5.05
3.38
5.09

5.38
5.23
5.27
5.08

BS-t
5.14

Adjusted-t
5.20

5.35
5.46
-

5.41
5.31
-

5.09

5.46

5.23
5.17
-

5.36
5.40
-

Table 2: Simulated Type I error under stratified permuted block design (SPB) and
complete randomization (CR) in % in the seamless trial with three treatments, one discrete
covariate and one continuous covariate.
MTP

(p1, p2, σ)

Simes

(0.5, 0.5, 1.0)
(0.4, 0.6, 1.0)
(0.4, 0.6, 1.5)

Dunnett

(0.5, 0.5, 1.0)
(0.4, 0.6, 1.0)
(0.4, 0.6, 1.5)

Allocation
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR

t-test
1.10
4.47

lm(Z1, Z2)
4.53
4.56

1.08
4.57
2.16
4.55

4.63
4.60
4.89
4.58

1.23
5.02

4.89
4.97

1.27
5.13
2.31
4.89

4.94
4.87
5.09
5.10

BS-t
5.45

Adjusted-t
5.16

5.14
5.31
-

5.20
4.96
-

5.78

5.41

5.46
5.66
-

5.19
5.31
-

Powers for different designs and analytical approaches were compared by assuming
differences in treatment effects in Table 3 (discrete case) and Table 4 (continuous case).
Multiple values of (  1 ,  2 ) with fixed ( p1 , p 2 ,  ) = (0.5,0.5,1) were investigated in the
numerical studies. For both cases, the two sample t-test had smaller power under the SPB
design than under CR when |  1 −  2 | was small, but larger power was observed when

|  1 −  2 | increased. Under the SPB randomization, the t-test with adjustment was more
powerful than the two sample t-test, regardless of the methods for multiplicity adjustment.
Similar power performance was identified among the t-test with adjustment, the bootstrap ttest and the full linear model under the SPB design in the discrete case, while the t-test with
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adjustment and the bootstrap t-test were slightly less powerful than the full linear model
when one of the covariates was continuous. In addition, the SPB design performed better
than CR regarding the number of replications that the better treatment was selected in both
discrete and continuous cases, especially when |  1 −  2 | was relatively large.
Table 3: Power comparison (in %) and number (M) of replications the better
treatment is selected for the confirmation stage under stratified permuted block design (SPB)
and complete randomization (CR) in the seamless trial with three treatments and two discrete
covariates.
MTP

(α1, α2)

Simes

(0.26, 0.16)
(0.24, 0.16)
(0.22, 0.16)
(0.20, 0.16)
(0.18, 0.16)

Dunnett

(0.26, 0.16)
(0.24, 0.16)
(0.22, 0.16)
(0.20, 0.16)
(0.18, 0.16)

Allocation
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR

t-test

lm(Z1, Z2)

BS-t

Adjusted-t

M

77.28
75.00
69.76
69.04
61.76
62.46
52.99
55.31
44.41
48.46
78.00
75.81
70.87
70.20
62.71
63.59
54.08
56.56
45.75
49.87

89.44
88.93
84.50
83.99
78.61
77.84
71.56
70.85
63.68
63.50
90.08
89.57
85.35
84.85
79.28
78.90
72.42
71.88
64.60
64.71

88.84
84.35
79.02
72.42
64.58
89.52
84.91
79.56
73.30
65.32
-

89.73
85.21
79.03
72.41
64.63
90.13
85.72
79.73
73.11
65.13
-

6667
6420
6374
6139
6042
5837
5697
5517
5370
5255
6667
6420
6374
6139
6042
5837
5697
5517
5370
5255
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Table 4: Power comparison (in %) and number (M) of replications the better
treatment is selected for the confirmation stage under stratified permuted block design (SPB)
and complete randomization (CR) in the seamless trial with three treatments, one discrete
covariate and one continuous covariate.
MTP

(α1, α2)

Simes

(0.26, 0.16)
(0.24, 0.16)
(0.22, 0.16)
(0.20, 0.16)
(0.18, 0.16)

Dunnett

(0.26, 0.16)
(0.24, 0.16)
(0.22, 0.16)
(0.20, 0.16)
(0.18, 0.16)

Allocation
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR

t-test

lm(Z1, Z2)

BS-t

Adjusted-t

M

57.32
58.74
49.72
52.97
42.33
47.53
35.27
41.96
28.76
36.72
58.49
60.41
50.85
54.21
43.66
49.07
36.42
43.20
29.70
38.15

88.96
88.92
84.42
83.95
78.44
78.06
71.84
71.25
64.26
63.77
89.48
89.37
84.90
84.85
79.41
78.85
72.44
72.30
65.61
64.75

79.31
73.39
67.08
59.71
52.83
80.17
74.39
68.07
60.92
53.77
-

79.31
73.71
67.36
60.41
53.12
80.14
74.54
68.04
61.28
53.89
-

6547
6154
6243
5970
5944
5709
5632
5495
5316
5278
6547
6154
6243
5970
5944
5709
5632
5495
5316
5278

Similar results on Type 1 error rates, power and the number of replications the best
treatment is selected for Stage II were obtained in numerical studies for Scenario 2 (Table 56) and Scenario 3 (Table 7-8).
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DISCUSSION
In practice, unadjusted analysis is widely used in clinical trials with CAR for
simplicity and to avoid model misspecification40,44,46. However, ignoring the stratification
covariates in the analysis may lead to a reduction in the Type 1 error rate and a decrease in
power40,44,46. In the current numerical study, the two sample t-test resulted in conservative
Type 1 error rates and decreased power under the SPB randomization as shown in previous
findings. The newly proposed t-test with adjustment well controlled the Type 1 error rate
under the SPB randomization with either Simes test or Dunnett test, consistent with the
theoretical results in Theorem 2 and Theorem 3. The bootstrap t-test has been shown to
control the Type 1 error rate at the nominal level under CAR in a single phase design with
Table 5: Simulated Type I error under stratified permuted block design (SPB) and
complete randomization (CR) in % in the seamless trial with four treatments and three
discrete covariates.
MTP

(p1, p2, p3, σ)

Simes

(0.5, 0.5, 0.5, 1.0)
(0.4, 0.5, 0.6, 1.0)
(0.4, 0.5, 0.6, 1.5)

Dunnett

(0.5, 0.5, 0.5, 1.0)
(0.4, 0.5, 0.6, 1.0)
(0.4, 0.5, 0.6, 1.5)

Allocation
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR

26

t-test
0.81
4.56

lm(Z1, Z2)
4.44
4.70

0.76
4.57
2.05
4.57

4.50
4.67
4.49
4.30

1.03
5.18

5.16
4.97

0.90
5.37
2.37
5.32

5.00
5.03
5.15
5.05

BS-t
5.00

Adjusted-t
5.19

5.16
5.22
-

4.93
4.76
-

5.58

5.75

5.66
5.78
-

5.42
5.24
-

two treatments45,46. Here the Type 1 error rate was also well controlled by the bootstrap t-test
under the SPB randomization in a seamless trial design.
Table 6: Power comparison (in %) and number (M) of replications the best treatment
is selected for the confirmation stage under stratified permuted block design (SPB) and
complete randomization (CR) in the seamless trial with four treatments and three discrete
covariates.
MTP

(α1, α2, α3)

Simes

(0.28, 0.16, 0.14)
(0.26, 0.16, 0.14)
(0.24, 0.16, 0.14)
(0.22, 0.16, 0.14)
(0.20, 0.16, 0.14)

Dunnett

(0.28, 0.16, 0.14)
(0.26, 0.16, 0.14)
(0.24, 0.16, 0.14)
(0.22, 0.16, 0.14)
(0.20, 0.16, 0.14)

Allocation
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR

t-test

lm(Z1, Z2)

BS-t

Adjusted-t

M

67.11
66.73
59.75
60.88
52.01
55.43
44.35
49.64
36.70
44.21
69.50
68.67
61.92
63.30
54.25
57.50
46.38
52.08
39.11
46.54

88.17
87.44
83.52
82.76
78.28
77.50
72.23
71.35
65.57
64.43
89.21
88.46
84.99
83.97
79.73
78.99
74.05
73.17
67.45
65.93

88.19
83.87
78.41
72.61
65.96
89.20
85.14
79.91
74.14
67.71
-

88.45
84.36
79.47
73.42
66.77
89.48
85.45
80.55
75.14
68.78
-

6006
5407
5565
5091
5138
4758
4741
4446
4276
4129
6006
5407
5565
5091
5138
4758
4741
4446
4276
4129

Higher power of the t-test with adjustment compared to the two sample t-test under
SPB randomization demonstrates the statistical advantage of the newly developed hypothesis
testing procedure, which had similar power performance as the bootstrap t-test and the
adjusted analysis using full linear model for the discrete case. When one stratification
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covariate was continuous, however, the t-test with adjustment and the bootstrap t-test were
less powerful than the full linear model, probably due to loss of information in discretizing
the continuous covariate for treatment allocation while failing to fully adjust for it in the
hypothesis testing process using the former two methods. In addition, the two sample t-test
had lower power under the SPB design compared to CR due to conservativeness of the test
when |  1 −  2 | was small. As |  1 −  2 | became larger, the power increased more rapidly
under SPB design than under CR, resulting in higher power under SPB randomization when

|  1 −  2 | was large. Similar results were observed from previous simulation studies under
CAR in the single phase design with two treatments45-47. Further theoretical research is
required to explain the pattern of power differences in the seamless trial setting.
Table 7: Simulated Type I error under stratified permuted block design (SPB) and
complete randomization (CR) in % in the seamless trial with five treatments and two discrete
covariates.
MTP

(p1, p2, σ)

Simes

(0.5, 0.5, 1.0)
(0.4, 0.6, 1.0)
(0.4, 0.6, 1.5)

Dunnett

(0.5, 0.5, 1.0)
(0.4, 0.6, 1.0)
(0.4, 0.6, 1.5)

Allocation
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR
SPB
CR
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t-test
1.24
4.82

lm(Z1, Z2)
5.01
4.34

1.19
4.59
2.37
4.61

4.31
4.32
4.48
4.62

1.63
5.06

5.10
5.14

1.53
5.15
2.98
5.26

5.22
5.09
5.05
5.12

BS-t
4.72

Adjusted-t
4.88

4.65
4.71
-

4.68
4.57
-

5.34

5.32

5.42
5.45
-

5.38
5.08
-

The probability that the best treatment is selected at the interim look to proceed is of
interest for clinical trial practitioners. Here the number of replications that the best treatment
is selected for Stage II was higher under the SPB design than under CR, indicating that the
best treatment was more likely to be selected under CAR according to the selection rule as
defined in formula (2). One intuitive explanation is that the covariates are more balanced
Table 8: Power comparison (in %) and number (M) of replications the best treatment
is selected for the confirmation stage under stratified permuted block design (SPB) and
complete randomization (CR) in the seamless trial with five treatments and two discrete
covariates.
MTP

(α1, α2, α3, α4)

Simes

(0.28, 0.16, 0.14, 0.12)
(0.26, 0.16, 0.14, 0.12)
(0.24, 0.16, 0.14, 0.12)
(0.22, 0.16, 0.14, 0.12)
(0.20, 0.16, 0.14, 0.12)

Dunnett

(0.28, 0.16, 0.14, 0.12)
(0.26, 0.16, 0.14, 0.12)
(0.24, 0.16, 0.14, 0.12)
(0.22, 0.16, 0.14, 0.12)
(0.20, 0.16, 0.14, 0.12)

Allocation t-test
70.74
SPB
70.09
CR
63.31
SPB
64.51
CR
55.79
SPB
58.43
CR
48.50
SPB
52.21
CR
40.83
SPB
46.15
CR
73.52
SPB
72.52
CR
66.30
SPB
67.20
CR
58.68
SPB
61.54
CR
51.42
SPB
55.30
CR
44.34
SPB
49.30
CR
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lm(Z1, Z2)

BS-t

Adjusted-t

M

85.67
85.27
81.11
80.38
75.56
74.93
69.24
68.08
62.19
61.34
87.28
87.04
82.78
82.38
77.79
76.83
71.72
70.82
64.53
63.68

86.16
81.45
75.97
69.82
62.98
87.62
83.19
78.13
71.94
65.24
-

86.29
81.77
76.66
70.36
63.12
87.58
83.34
78.51
72.54
65.73
-

5142
4666
4692
4326
4304
4033
3896
3679
3547
3350
5142
4666
4692
4326
4304
4033
3896
3679
3547
3350

between treatment arms under the SPB randomization, which decreases the standard error of
the treatment effect estimate and thereby increases precision in the estimation. The improved
precision of the estimated treatment difference can also explain the greater statistical power
of the trial under CAR than under CR in the seamless design.

CONCLUSION
In this study, numerical simulations were conducted to investigate the feasibility and
advantages of a newly developed hypothesis testing approach in the seamless phase II/III
design with CAR. The proposed method has been shown to well control the Type 1 error rate
around the nominal level and increase the statistical power compared to the two sample t-test,
which is not valid under CAR but still commonly used in clinical trials with such a design.
One reason that practitioners perform unadjusted analysis, such as the two sample ttest instead of the adjusted analysis in clinical trials with CAR is that model misspecification
may occur when using linear regression models for covariate adjustment44,46. In practice, the
underlying response model is usually unknown and the covariate effects may be not linearly
additive on responses. For example, a stratification covariate may have a non-linear form or
correlate with other stratification covariates. Under these scenarios, fitting a full model
incorporating all stratification covariates in a linearly additive pattern in adjusted analysis
will lead to biased standard errors44. Therefore, future numerical studies to investigate the
performance of the newly developed hypothesis testing approach in different situations of
model misspecification are of great interest. Another interesting future direction is to
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examine the hypothesis testing procedure in a seamless design with CAR by simulations
using parameters from real trial data, which could further promote its application in practice.
For simplicity, the current numerical study assumed that multiple experimental
treatments were compared with one control, i.e., a placebo, and primary endpoint was
evaluated at the interim look. The selection rule used at the end of Stage I was derived from a
previous study, which selected treatments to continue based on standardized treatment
effects48. In practice, multiple experimental treatments are often compared with active
controls that are known, effective treatments besides placebo. Treatment selection is based on
a threshold value, which is the maximum of Minimal Clinically Important Difference
(MCID)49 and treatment effects of the active controls against placebo. Experimental
treatments with effects larger than the threshold value or the closest to that value if no
treatment effect exceeds are selected to continue to Stage II50. In addition, early endpoint is
evaluated at the interim analysis for treatment selection when the primary endpoint of interest
is only available after long-term follow-up in practice51. Selection methods for incorporating
early endpoint data in the seamless trials have been proposed by Stallard52 and Friede et al53.
It will be interesting to investigate the proposed hypothesis testing procedure by numerical
studies that implement the above selection designs.
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